Is HQL or HTGC more undervalued in 2026?

CirclFi compares TeklaLife Sciences Investors (HQL) and Hercules Capital, Inc. (HTGC) using 13 institutional-grade valuation models. HQL has a Quality of Company score of 1.9/10 while HTGC scores 6.8/10.

Which is a better buy — HQL or HTGC?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do HQL and HTGC valuations compare?

HQL at $17.67 and HTGC at $15.42 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

HQL vs HTGC Valuation Comparison 2026 — Intrinsic Value Analysis

HQL

Asset Management

TeklaLife Sciences Investors

Quality

1.9

out of 10

Value Trap

—

Price

$17.67

Last close

Models

8/13

Active

HTGC

Asset Management

Hercules Capital, Inc.

Quality

6.8

out of 10

Value Trap

WARN

Price

$15.42

Last close

Models

12/13

Active

Model-by-Model Comparison

Model	Type	HQL Fair Value	HQL Upside	HTGC Fair Value	HTGC Upside
Bayesian DCF	Intrinsic	$4.68	-73.5%	$2.68	-83.0%
Earnings Power Value	Intrinsic	—	—	$1.71	-89.6%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$71.50	+307.4%	$40.08	+159.9%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for HQL vs HTGC — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

HQL vs HTGC — Which Stock Is More Undervalued?

HTGC scores higher with a 6.8/10 quality rating vs HQL's 1.9/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing TeklaLife Sciences Investors (HQL) and Hercules Capital, Inc. (HTGC) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

HQL currently trades at $17.67 with a QOC of 1.9/10, while HTGC trades at $15.42 with a QOC of 6.8/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).